Abstract The purpose of this study is to compare immunohistochemistry (IHC) and cytosol-based assays for determination of estrogen receptor (ER) and prediction of response to adjuvant tamoxifen treatment in postmenopausal women with early-stage invasive breast cancer. The Stockholm Breast Cancer Study Group conducted a randomized trial during 1976 through 1990 comparing adjuvant tamoxifen versus control. The patients were stratified according to tumor size and lymph node status in high-risk and low-risk groups. In this study we evaluated 683 patients with ''low risk'' breast cancer (size B30 mm, lymph nodenegative) for whom ER status had been determined by both the cytosol assays and IHC at one pathology laboratory. The median follow-up was 17 years. Six hundred eighty-three patients had tumors with ER determined by both methods, 536 (78.5%) were ER-positive by cytosol assays using the cutoff level at C0.05 fmol/lg DNA and 539 patients were ER-positive (79%) by IHC using the cutoff level at C10% cell stained. Thirty-nine tumors (5.7%) were ER-positive by cytosol but not by IHC, whereas the opposite pattern was found for 42 cases (6.1%). Only seven tumors had stained cells between 0 and 9% by IHC. The concordance between IHC and cytosol assays was high (88%). The kappa statistic was 0.65, 95% CI 0.58-0.72. Among patients classified as ER-negative no therapeutic benefit from tamoxifen was observed. Among patients with ER-expressing tumors, tamoxifen resulted in significantly better recurrence-free survival irrespective of the method (IHC: HR, 0.53, P \ 0.001; cytosol: HR, 0.53, P \ 0.001). The effect on overall survival was not statistically significant probably due to the limited sample size. Both IHC and cytosol assay accurately predict long-term response to adjuvant tamoxifen.
debate. Earlier studies reported a more favorable prognosis for patients with ER-positive tumors [4] [5] [6] , while later studies showed that the early advantage for ER-positive breast cancers was not sustained over time [7] [8] [9] . Furthermore, we previously reported a frail prognostic value for ER [10] and that the better outcome for patients with ER-positive tumors is obvious only for patients who received endocrine therapy.
Before approximately 1990 determination of ER and PGR was based on biochemical methods, which measured the level of receptors in cytosol initially by a ligand binding assay, later replaced by monoclonal antibodybased assays. Cytosol assays were time-consuming, expensive and required fresh tissue and measured receptor content in both cancer cells and normal cells in the tumor tissue. However, an advantage of the cytosol method was that it offered quantitation of the receptor levels. On the other hand, Immunohistochemistry (IHC) has many advantages compared with cytosol methods. It is cheaper, faster, and does not require fresh material. Furthermore, it is possible to perform on small amounts tumor cells, and ER and PGR are measured in cancer cells only.
A high concordance between biochemical and immunochemical methods was reported in several studies [11] [12] [13] [14] . IHC and cytosol assays were shown to yield similar predictive and prognostic information [15] [16] [17] , but the majority of these studies had a short follow-up and many patients received a range of therapies. To our knowledge there are only few studies comparing these methods in an adjuvant randomized setting [17] [18] [19] .
The aim of this study was to compare the predictive value of ER measured in the cytosol of the unfixed tumor with ER status obtained by an immunohistochemical assay performed on archival tissue. For this, we used tumors from a well-defined randomized clinical adjuvant trial conducted by Stockholm Breast cancer Group where high quality data on long-term follow-up is available. We furthermore investigated the extent to which the methods of assessing the hormone receptors may affect trial conclusions.
Materials and methods

Study design
Patients with an operable invasive breast cancer entered in a controlled clinical study of adjuvant endocrine therapy conducted by the Stockholm Breast Cancer Study Group, the Stockholm Adjuvant Tamoxifen Trial (STO-3). The trial was approved by the local ethical committee and the details of this study were described previously [20] . Postmenopausal women at the age of 70 or less with invasive breast cancer were randomly given tamoxifen postoperatively at a dose of 40 mg per day compared with no adjuvant endocrine therapy. A woman was considered postmenopausal if more than 6 months had emerged since her last menstrual period. During November 1976 through June 1990, a total of 2,738 patients entered the trial. The trial included patients irrespective of hormone receptor content but prospectively collected data on ER status were available in 2012 (85%) patients. ER status was absent mainly in patients with small tumors from which all tissue was used to verify the histopathological diagnosis of breast cancer.
Before randomization the patients were stratified according to stage of disease and primary therapy. 1,780 patients (65%) with no lymph node metastases and a tumor diameter of 30 mm or less (established by histological examination) were classified as ''low risk.'' In this group, 432 patients were treated with breast conserving surgery including axillary dissection plus radiation to the breast (50 Gy/5 weeks). The remaining 1,348 patients had a modified radical mastectomy.
Present study population
For the purpose of this study, we selected the 1,780 ''low risk'' patients because they received no adjuvant chemotherapy known to affect recurrence-free survival (RFS) and overall survival (OS). These patients were randomized between no systemic therapies versus tamoxifen in contrast to a high-risk group also given chemotherapy. The data on the estrogen receptor (ER) status were known for 1,183 (66.5%) which was originally determined by cytosol assays. Tumor material was available for 1,001 of these 1,780 patients. From 912 of these 1,001 tumors, tissue microarray (TMA) could be created and sections stained for ER by IHC, for the 89 remaining patients the archival material was of poor quality or not representative (e.g., cancer in situ, normal cells, and connective tissue). 790 of 912 tumors were technically evaluable by IHC and the remaining was difficult to interpret because of too few tumor cells. Data on ER receptor by cytosol for 777 of 912 patients were available. Re-evaluation was performed on 683 patients for whom the ER status was known by both cytosol and IHC (Fig. 1) .
Follow-up strategies
Clinical visits took place once every 3 months during the first 2 years, every 6 months during 2-5 years, and yearly thereafter. These visits routinely included a physical examination and an annual mammogram. Chest X-ray, blood sample, bone scans, etc. were performed if clinical symptoms and signs indicated a probable relapse. Disease recurrence was confirmed when possible by biopsy.
However, bone and visceral metastases were sometime established on unequivocal radiological evidence. Recurrence was dated from the first evidence of relapse based on physical, histological, or imaging data. After recurrence, treatment was decided individually. The current results were based on follow-up until December 31, 2005 . The proportion of patients lost to follow-up before this date was \1%.
ER determination
The ER cytosol assays were performed in one laboratory in Stockholm, a participant in the Swedish national wide quality control program for hormone receptor laboratories sponsored by the Swedish Cancer Society. Representative tumor sample was collected immediately after surgery and transported to the laboratory in saline according to the guidelines in the study protocol. The samples were frozen and stored at -80°C for 2 weeks or less. After thawing, the content of ER was determined using isoelectric focusing (IF) on polyacrylamide gel as previously described [21, 22] . This technique was used for samples assayed before 1988. After 1988 an enzyme immunoassay (EIA) was used. Studies have showed that results with these techniques correlate well with those obtained using methods based on ultra centrifugation, dextran-coated charcoal, and monoclonal antibodies [21] [22] [23] [24] . The receptor values in this study were normalized to DNA content as measured by Burton to avoid the influence of the large variations in extracellular protein [25] . A tumor with a receptor content of C0.05 fmol/lg DNA was classified as ER-positive. This cutoff point was chosen since a previous analysis indicated that it distinguished between patients who benefited from adjuvant tamoxifen and those who did not.
Immunohistochemistry
The immunohistochemical staining was performed using the Ventana HX automatic system BenchMark (Ventana Medical System, SA IllKirch, Cedex, France). A rabbit monoclonal ER antibody (SRi, Ventana) was used. Antigen retrieval and staining procedure were performed according to the instruction by the Ventana manufacture. Positive controls were run with each batch. Only the invasive part of the carcinoma was assessed and for each case all three cores were reviewed. The receptor levels presented are based on an average of the three cores. The proportion of stained nuclei was recorded as 0, 1% or more but less than 10%, 10% or more but less than 25%, 25% or more but less than 50%, 50% or more but less than 75% and 75% or more. The scoring was done by two pathologists (B.L; L.S.).
Statistics
Overall survival and RFS were estimated by the KaplanMeier method. The end-point in calculations of RFS was loco-regional recurrence, distant recurrence, or death due to breast cancer. Hazard ratios (HR) were estimated using the Cox's proportional hazards model. The pattern of the treatment effect of tamoxifen for different ER values of both cytosol and IHC was studied. For this purpose, Subpopulation Treatment Effect Pattern Plots (STEPP) analysis [26] was performed. The method used was the tailoriented version with g = 7, generating 13 overlapping subgroups (six for decreasing ER values, one for all patients, and six for increasing ER values). The STEPP plots show the tamoxifen effect estimated in each of these created subgroups.
The sensitivity and specificity corresponding to different choices of cutoff for ER cytosol values compared to ER determined by IHC were explored using a Receiver Operating Characteristic curve (ROC). For this analysis the cutoff for ER-positivity by IHC was set to 10% stained cells. The software used for the statistical analysis was Stata/SE 10.0.
Results
Clinical characteristics
Among 1,780 postmenopausal patients with ''low-risk'' invasive breast cancer randomly assigned to treatment in the STO-3 trial, 1,183 patients (66. 5%) had ER-positive disease, 296 (16.6%) had ER-negative disease, and the remaining 301 patients (17%) had unknown ER status. Median follow-up was 17 years. The tamoxifen and control groups were well balanced regarding clinical characteristics (Table 1) . Among 912 women with tumor material available in TMA, ER had been determined in the cytosol in 777 cases (85%) and by IHC in 790 cases (86.5%). ER was determined by both methods in 683 tumors (75%) described below. The clinical characteristics of patients in this study and patients in ''low-risk group'' of the STO-3 trial were comparable (Table 1) . However, in this study, there were fewer patients with tumor size less than 10 mm than the low-risk group (22 and 31%, respectively) and more patients with tumor size 11-30 mm (76 and 65%, respectively). The other dissimilarity was that all patients in this cohort have a known ER status, but in the ''low-risk'' population 17% had unknown ER status.
Concordance between the methods
Six hundred eighty-three patients had tumors with known ER status by both methods, 536 (78.5%) were ER-positive by cytosol assays (ER C 0.05 fmol/lg DNA) and 539 ER-positive (79%) by IHC (ER C 10%). Thirty-nine (5.7%) had ER-positive cytosol assays but negative IHC, whereas the opposite pattern was found in 42 cases (6.1%) ( Table 2 ). ER status from cytosol assays indicated that 147 (21.5%) of 683 tumors were ER-negative. When the ER status of these ER-negative tumors by the cytosol assays was determined by IHC, 42 (28.5%) were ER-positive. Of 536 tumors classified as ER-positive by the cytosol assays, 39(7%) were classified as ER-negative by IHC. The concordance between the two assays was high (88%). The kappa statistic for concordance was 0.65 (CI 0.58-0.72), when using two categories (ER-positive and ER-negative) for each method. Only seven tumors were classified into the low category by IHC (1-9% of cells stained). (Fig. 3) . Overall mortality was slightly reduced by tamoxifen treatment but the differences were not statistically significant, likely due to a relatively low power. However the treatment benefit with tamoxifen appeared to be marginally greater among those classified as ER-positive by cytosol assays compared to those classified with IHC assay (HR 0.80 and 0.87, respectively) (Fig. 3) tumors (38%) and ER C 85%/279 tumors (41%) by IHC). The analyses revealed that there was no benefit of tamoxifen among patients with ER-negative by any assays. Among patients with ER-positivity defined by IHC, the benefit from tamoxifen appeared to be unrelated to the percentage stained cells, but in the group with ER-positivity measured by cytosol assays the benefit from tamoxifen treatment appeared to be related to the ER concentration and an increased benefit with ER (C1.0 fmol/lg DNA (data not shown).
To investigate the trends in tamoxifen treatment effect differences across the continuum of ER status, we performed STEPP analyses (Fig. 4) . The STEPP curves show the effect of tamoxifen for overlapping subgroups with different median ER values by cytosol (Fig. 4a ) and by IHC (Fig. 4b) . The STEPP curve for ER determined by IHC does not start with a zero point on log relative hazard indicating some effect of tamoxifen in patients with low ER value by IHC. The Kaplan-Meier curve of RFS for tamoxifen effect for ER IHC -negative(ER \ 10%) shows as well the same trend (Fig. 2b) . Likewise, the STEPP curve of IHC has a shallow slip in comparison to the STEPP curve of cytosol that shows an obvious trend in tamoxifen effect with greater effect in subpopulation with higher median ER content. However, based on these analyses we were unable to identify an abrupt changing in tamoxifen effect separating the subpopulations without effect from the subpopulations with effect from tamoxifen. Further statistical analyses by ROC curves and testing different cutoff levels for cytosol (0.01 fmol/lDNA and 0.05 fmol/lDNA) and IHC (1, 10 and 20%), to identify an optimal cutoff level for both assays, were performed. However, the ROC curve which was created by choosing different cutoff level for ER cytosol values, compared to ER determined by IHC and if the cutoff level for considering ER to be positive by IHC, was set to 10%, showed that the majority of tumors were correctly classified with a cutoff level for cytosol from 0.05 to 0.08 fmol/lDNA (between 88.1 and 88.4% with sensitivity 92.2-90.7% and specificity 72.9-79.9%, respectively) (Fig. 5a) . The sensitivity and specificity corresponding to cutoff of 10% for ER determined by IHC compared to ER cytosol values and if the cutoff level for considering ER to be positive by cytosol was chosen 0.05 fmol/lDNA, was 92.7 and 71.4, respectively, and 88.1% of the tumors could (Fig. 5b) . It means that these two cutoff levels (10% by IHC and 0.05 fmol/lDNA) are likely to be corresponding. We also conducted STEPP analysis for the two discordant groups: ER-positive by IHC but negative by cytosol (42 cases) and ER-negative by IHC but positive by cytosol (39 cases). The STEPP analyses of these two subgroups were not conclusive because of the small number of cases in each group (data not shown). On the other hand, the Kaplan-Meier plots of RFS for tamoxifen effect in the discordant subgroup of ER-negative by cytosol (ER \ 0.05 fmol/lg DNA) but positive by IHC (ER C 10%) revealed similar effect for both tamoxifen and control group (Fig. 6a) . In contrast, the RFS in the discordant subgroup, which was defined as ER-positive by cytosol (ER C 0.05 fmol/lg DNA) but negative by IHC (ER \ 10%), was greater in the tamoxifen group compared with the control group (Fig. 6b) . These results may indicate some more predictive ability of cytosol assays compared to IHC assay. However, this difference was not statistically significant and should be interpreted with caution because of the small number of patients in these groups. An analysis of events by period of follow-up showed that disease recurrences and total deaths were reduced among the tamoxifentreated patients mainly during the first 5 years (Table 3) .
Discussion
The results from randomized studies in the 1970s changed the treatment of early-stage breast cancer and established adjuvant tamoxifen therapy for ER-positive breast cancer [20, 27, 28] . However, the importance of ER status as a predictor was not completely established until 1990 [29] . The Stockholm adjuvant trial (STO-3) conducted by the Stockholm Breast Cancer Study Group was initiated in 1976. This study is one of the largest of adjuvant systemic therapy versus no adjuvant treatment. Inclusion was not based on hormone receptor status, although prospective data on receptor status were available for 85% of the patients. This has permitted evaluations of the treatment predictive ability of ER. This report is based on the ''lowrisk'' subpopulation of STO-3. The follow-up is long and few patients were lost to follow-up. Our data confirm that ER status measured by IHC is similar to that determined by the cytosol assays. The result showed no benefit from tamoxifen therapy for ER-negative patients regardless of assays performed. The pattern of the tamoxifen effect was similar for patients with absent staining cells (ER = 0%) compared to ER-negative (ER \ 10%). However, only 7 tumors were stained between 1 and 9%. Patients with ER-positivity defined by IHC or cytosol assay obtained similar benefit from tamoxifen treatment. In discordant groups the effect of tamoxifen in term of RFS showed dissimilarity. There were no differences between the tamoxifen group and the no tamoxifen group in ER cyt -negative/ER IHC -positive, despite the majority of cytosol negative tumors showing high percent staining cells by IHC. In contrast, the tamoxifen group showed greater RFS compared to the no tamoxifen group in ER cyt -positive/ER IHC -negative discordant group. Whether this indicates a more sensitive predictive ability for cytosol assay or is a result by chance due to very small number of cases in each group needs further validation from other studies. There may also be the possibility that the larger amount of fresh tissue used in the cytosol method The subset of patients in trial IX is similar to our cohort but randomization was between chemotherapy followed by tamoxifen versus tamoxifen. The median duration of follow-up was shorter, and biochemical assays were performed at different local pathology laboratories [19] . However, our results confirm results from these cohorts. There is no general consensus concerning the ER cutoff level separating endocrine responsive tumors from nonresponsive one. In STO 3 trial a cutoff level of 0.05 fmol/ lg DNA was used to distinguish receptor-positive tumors from receptor-poor/receptor-negative tumors. Analysis of treatment benefit versus ER levels did not show any benefit for ER levels below 0.05 fmol/lg DNA [32] . In this study we used this cutoff level for cytosol assays. On the other hand, the IHC method has increasingly been used for determination of ER during recent decades and has been established as the routine assay for ER determination. Concerns associated with IHC assay which reduce its accuracy include variation in pre-analytical, analytical and post-analytical procedures, using different antibodies and diversities in interpretation and reporting results from IHC assays for determination of ER in breast cancer. To overcome this issue standardization of handling tissue, procedures, use of antibodies, interpretation and reporting result has been discussed and recently the American Society of Clinical Oncology (ASCO) and the college of American Pathologists (CAP) presented a guideline recommendations for IHC testing of ER and PR to improve accuracy of the method [33] . The second issue is to find a optimal cutoff level for IHC. For the immunohistochemical assay we used 10% stained cells as cutoff level that has been commonly used worldwide. Some recently data provide support for the use of cutoff level of 1% staining cells for ER as showing a better prognosis or some extent of endocrine effect [31, 33, 34] . However, the 11th St Gallen conference defined endocrine responsiveness as the presence of any detectable ER [35] . Our study could neither support nor reject these statements since only a small number of tumors had stained cells between 0 and 25%.
Some limitations of this cohort must be taken into account when interpreting the results. This study included only 38% of patients randomly allocated in the ''low-risk'' group. Although the clinical characteristics of patients in this study and those of the overall trial were comparable, the statistical power is reduced. The other limitation is the issue of cut point for Immunohistochemical assays. Only seven tumors had between 0 and 9% stained cells. We are thus unable to suggest an optimal cut point for the IHC assay. Finally, a direct comparison of outcomes (e.g., RFS and OS) between patients whose tumors were estrogens receptor absent or negative by IHC and positive by cytosol assay with patients whose tumors were estrogen-positive by IHC but negative by cytosol assay was not meaningful because of the small number of tumors with discordant data.
Conclusion
We conclude that determination of ER status by IHC could substitute cytosol assays with preserved ability to predict response to adjuvant tamoxifen treatment of early-stage breast cancer. However, we observed 12% discordance in ER status determined by IHC as compared to cytosol assays. In spite of this, ER status determined by IHC confirmed randomized clinical trial results that were based on predicted response to tamoxifen therapy as well as ER status measured by cytosol assay.
